/

Empresas

Sk

No verificado

SkylineDx

Sobre qué escribimos

BiologíaCienciaFarmacéuticaMedio Ambiente/EcologíaSanidad

15 Comunicados de prensa

Ver todos los comunicados de prensa

Press Release cover image

25/03/2026

Salud

Fitness

Medicina - Varios

Medio Ambiente/Ecología

Agricultura

Merlin CP-GEP™ Demonstrates Superior Predictive Accuracy for Sentinel Lymph Node Metastasis in Early-Stage Melanoma

Fuente

Editor

1.00

0

05/03/2026

Salud

Fitness

Medicina - Varios

Ciencia

Medio Ambiente/Ecología

Agricultura

SkylineDx Launches a Guideline-Informed Risk Assessment Initiative to Support SLNB Decision-Making in Early-Stage Melanoma

Fuente

Editor

1.00

0

22/07/2025

Salud

Fitness

Medicina - Varios

Medio Ambiente/Ecología

Agricultura

SkylineDx's Merlin Melanoma Assay shows its ability to reduce SLNB by over 40% in a Danish Multicenter Validation Study

Fuente

Editor

1.00

0

08/07/2025

Salud

Fitness

Medicina - Varios

Medio Ambiente/Ecología

Agricultura

Independent Meta-Analysis Shows SkylineDx's Merlin CP-GEP Assay Accurately Stratifies Patients for Sentinel Lymph Node Biopsy Selection

Fuente

Editor

1.00

0

02/06/2025

Farmacéutica

Sanidad

Ciencia

SkylineDx Highlights Merlin Assay's Power to Predict Recurrence Risk of Head and Neck Melanoma Without Sentinel lymph node Biopsy at ASCO 2025

Fuente

Editor

1.00

0

04/04/2025

Farmacéutica

Sanidad

Biología

SkylineDx Presents Landmark Study on Merlin CP-GEP beyond SLNB prediction: Transforming Melanoma Risk Assessment

Fuente

Editor

1.00

0

28/03/2025

Farmacéutica

Sanidad

Ciencia

Biología

SkylineDx presents landmark findings from the largest prospective multicenter melanoma GEP trial at SSO 2025

Fuente

Editor

1.00

0

12/03/2025

Farmacéutica

Sanidad

Economía

Start-up

Biología

SKYLINEDX ANNOUNCES NEW STUDY DEMONSTRATING ENHANCED RISK STRATIFICATION FOR SENTINEL LYMPH NODE BIOPSY IN HEAD AND NECK MELANOMA USING THE ADVANCED MERLIN CP-GEP TEST

Fuente

Editor

1.00

0

28/02/2025

Farmacéutica

Sanidad

Biología

SKYLINEDX ANNOUNCES NEW PUBLICATION ON SKY92 GENE EXPRESSION PROFILING TEST in DEFINING ULTRA-HIGH-RISK MULTIPLE MYELOMA

Fuente

Editor

1.00

0

07/12/2024

Farmacéutica

Sanidad

Ciencia

New Data from PROMMIS Study Highlights the Power of SKY92 in Identifying High-Risk Multiple Myeloma Patients

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0